<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752335</url>
  </required_header>
  <id_info>
    <org_study_id>FRC-TOC-2009-01</org_study_id>
    <secondary_id>2010-018658-12</secondary_id>
    <nct_id>NCT01752335</nct_id>
  </id_info>
  <brief_title>Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>TOCRIVAR</acronym>
  <official_title>Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tocilizumab changes the cardiovascular risk&#xD;
      factors on patients with arthritis rheumatoid.&#xD;
&#xD;
      Study hypothesis: the IL-6 contributes to increase the cardiovascular risk factors of&#xD;
      patients with rheumatoid arthritis because it produces systemic effects as increasing weight&#xD;
      and atherogenic body fat, changing energy homeostasis and inducing the adipokines production&#xD;
      and the insulin resistence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Framingham Point Scores</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Proportion of changes in Framingham Point Scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>Baseline, 12, 24 and 52 weeks</time_frame>
    <description>Number of patients with liver enzymes elevated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein levels</measure>
    <time_frame>Baseline, 12, 24 and 52 weeks</time_frame>
    <description>Number of patients with elevated lipoprotein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 score</measure>
    <time_frame>Baseline and 52 week</time_frame>
    <description>Variation in DAS28 score after tocilizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Drug Reactions</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Number of patients with Adverse Drug Reactions as a measure of safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinemia</measure>
    <time_frame>Baseline and 52 week</time_frame>
    <description>Change in insulinemia 52 weeks later.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of brachial artery vasodilation</measure>
    <time_frame>Baseline, 24 and 52 weeks</time_frame>
    <description>To evaluate the endothelial responses to ischemia and vasodilatation by ecography</description>
  </other_outcome>
  <other_outcome>
    <measure>cytokines, adipokines and adhesion molecules levels</measure>
    <time_frame>Baseline and 52 week</time_frame>
    <description>To evaluate changes in cytokines, adipokines and adhesion molecules</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>tocilizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.&#xD;
Usually 8mg/kg (not minor than 480 mg), once each 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Braquial ecography</intervention_name>
    <description>At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.</description>
    <arm_group_label>tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and &lt;70 years.&#xD;
&#xD;
          2. Diagnosis of active Rheumatoid Arthritis, moderate to severe (≥ 3.2 DAS28) of ≥ 6&#xD;
             months duration.&#xD;
&#xD;
          3. Patients with an inadequate clinical response to a stable dose of non-biological&#xD;
             DMARDs or anti-TNF treatment for a period ≥ 8 weeks before treatment.&#xD;
&#xD;
          4. If patients are receiving oral corticosteroids, the dose should have been ≤ 10 mg&#xD;
             predinosona and stable for at least one month before the start of treatment (day 1).&#xD;
&#xD;
          5. Patients who are able and wish to sign the informed consent and comply with the&#xD;
             requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery (including joints surgery) within eight weeks prior to the screening&#xD;
             visit or major surgery scheduled for six months after first infusion.&#xD;
&#xD;
          2. Other Rheumatic autoimmune diseases, including systemic lupus erythematosus (SLE),&#xD;
             mixed connective tissue disease (MCTD), scleroderma, polymyositis or systemic&#xD;
             involvement secondary to AR (such as vasculitis, pulmonary fibrosis or Felty's&#xD;
             syndrome). It's allowed the inclusion of patients with interstitial pulmonary fibrosis&#xD;
             and be still able to tolerate treatment with MTX. Sjögren's syndrome with RA is not&#xD;
             considered exclusion criterion.&#xD;
&#xD;
          3. Rheumatoid arthritis with Functional Class IV as defined in the RA Classification of&#xD;
             the ACR (complete or significant disability of patients, confined to bed or to the&#xD;
             wheelchair and without possibilities to take care themselves).&#xD;
&#xD;
          4. Prior or actual inflammatory joint disease different of RA (eg, gout, reactive&#xD;
             arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease).&#xD;
&#xD;
             Specific drug criteria&#xD;
&#xD;
          5. Treatment with any investigational agent in the four weeks before the screening visit&#xD;
             (or time equivalent to five half-lives of the investigational drug, whichever is&#xD;
             longer).&#xD;
&#xD;
          6. Immunization with a live vaccine / attenuated in the four weeks prior to the baseline&#xD;
             visit.&#xD;
&#xD;
          7. Pretreatment with TCZ Laboratory Tests (at the screening visit)&#xD;
&#xD;
          8. Serum creatinine&gt; 142 mmol / l (1.6 mg / dL) in women and&gt; 168 mmol / l (1.9 mg / dl)&#xD;
             in men and absence of active renal disease.&#xD;
&#xD;
          9. ALT (SGPT) and AST (SGOT)&gt; 1.5 ULN (if the initial sample of ALT [SGPT] or AST [SGOT]&#xD;
             gives a value&gt; 1.5 times ULN, you can take and analyze a second sample during the&#xD;
             selection period).&#xD;
&#xD;
         10. Platelet count &lt;100 x 109 / l (100.000/mm3).&#xD;
&#xD;
         11. Hemoglobin &lt;85 g / dl (&lt;8.5 g / l, 5.3 mmol / l).&#xD;
&#xD;
         12. Leukocytes &lt;1.0 x 109 / l (1000/mm3), ANC &lt;0.5 x 109 / L (500/mm3).&#xD;
&#xD;
         13. RAL &lt;0.5 x 109 / L (500/mm3).&#xD;
&#xD;
         14. Positivity for surface antigen of hepatitis B (HBsAg) and antibodies to hepatitis C.&#xD;
&#xD;
         15. Total bilirubin&gt; ULN (if the initial sample of bilirubin&gt; ULN, you can take and&#xD;
             analyze a second sample during the selection period).&#xD;
&#xD;
         16. Triglycerides&gt; 10 mmol / l (&gt; 900 mg / dl) at the screening visit (non fasting).&#xD;
&#xD;
         17. Pregnant or lactating women.&#xD;
&#xD;
         18. not use of reliable means of contraception, such as a physical barrier (patient and&#xD;
             partner), pill or contraceptive patch, spermicide and barrier or IUD.&#xD;
&#xD;
         19. Background of serious allergic or anaphylactic reactions to human monoclonal&#xD;
             antibodies, humanized or murine.&#xD;
&#xD;
         20. RXT evidence of clinically significant abnormality.&#xD;
&#xD;
         21. Evidence of uncontrolled concomitant serious illness, cardiovascular, nervous system,&#xD;
             lung (including obstructive pulmonary disease), renal, hepatic, endocrine (including&#xD;
             uncontrolled diabetes mellitus), or gastrointestinal.&#xD;
&#xD;
         22. history of diverticulitis, diverticulosis in antibiotic treatment, the physician&#xD;
             should consider the benefit-risk ratio.&#xD;
&#xD;
         23. Background of lower GI ulcer disease as the Crohn's disease, ulcerative colitis or&#xD;
             other symptomatic conditions predisposed to perforations lower GI&#xD;
&#xD;
         24. Uncontrolled diseases such as asthma, psoriasis or inflammatory bowel disease,...&#xD;
             treated normally with corticosteroids orally or parenterally.&#xD;
&#xD;
         25. Ongoing liver disease as determined by the principal investigator. (Patients with a&#xD;
             history of elevated ALT (SGPT) will not be excluded)&#xD;
&#xD;
         26. Active infections or recurrent infections in the past by mycobacteria, fungus, virus&#xD;
             or bacteria (for example: tuberculosis, atypical mycobacterial disease, clinically&#xD;
             significant abnormalities in RXT, hepatitis B and C, herpes zoster), or any major&#xD;
             episode infection that required hospitalization or IV antibiotic treatment in the 4&#xD;
             weeks preceding the screening visit or oral antibiotic in the 2 weeks prior to the&#xD;
             screening visit.&#xD;
&#xD;
         27. Primary or secondary immunodeficiency.&#xD;
&#xD;
         28. Evidence of active malignancy diagnosed within 5 years before the inclusion(including&#xD;
             solid tumors and hematological), or breast cancer diagnosed in the previous 5 years.&#xD;
&#xD;
         29. Active tuberculosis (TB) requiring treatment within 3 years above. Patients with a&#xD;
             positive skin test tuberculin purified protein derivative (PPD) at the screening&#xD;
             visit. Patients treated for tuberculosis no recurrence in the last three years will&#xD;
             not be excluded.&#xD;
&#xD;
         30. HIV positive patients.&#xD;
&#xD;
         31. History of alcoholism, drug addiction or drug abuse in the six months before the&#xD;
             screening visit.&#xD;
&#xD;
         32. Painful neuropathies or other conditions that may interfere with the pain assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Díaz González, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis, tocilizumab, cardiovascular risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 28, 2018</submitted>
    <submission_canceled>July 17, 2018</submission_canceled>
    <submitted>July 17, 2018</submitted>
    <returned>January 14, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

